Dissertation > Excellent graduate degree dissertation topics show

The Comparsion of the Efficacy and Safety in FOLFOX of Three Weeks and FOLFOX of Two Weeks in Stage Ⅲ Colon Cancer Adjuvant Chemotherapy

Author: PeiFuLai
Tutor: SunXiuHua
School: Dalian Medical University
Course: Oncology
Keywords: Colon cancer chemotherapy FOLFOX regimen DFS adversereaction
CLC: R735.35
Type: Master's thesis
Year: 2013
Downloads: 12
Quote: 0
Read: Download Dissertation


Objective:Compare the DFS in FOLFOX of three weeks with FOLFOX of two weeks inadjuvant chemotherapy for stage III colon cancer patients, the DFS in each subgroupand the incidence rate of adverse reaction in two kinds of scheme and seek theinfluencing factors of the DFS of stage III colon patients after operation.Method:This study use retrospective research method of case analysis, select the78inpatient from January1,2006to December31,2009in the Second Affiliated TumorHospital of Dalian Medical University from the Department of Internalmedicine-oncology, who is in stage III colon cancer after operation (condition ofentering the group for this retrospective analysis is below), the chemotherapy regimensused is FOLFOX scheme of three weeks or FOLFOX scheme of two weeks, Comparethe DFS in the two differert chemotherapy regimens in adjuvant chemotherapy for stageIII colon cancer patients, the DFS in each subgroup and the incidence rate of adversereaction in two kinds of scheme and seek the influencing factors of the DFS of stage IIIcolon patients after operation. All patients clinical data introduce into Excel, DFS is theinterval which start from postoperative to clinical metastasis of first or recurrence. Alldata are analyzed by SPSS16.0, t test is used to calculate the DFSof two groups and thesubgroups of DFS, the incidence rate of adverse reaction are analyzed by chi-square test,the influencing factors of DFS are analyzed by COX regression, t test and chi-squaretest have significant difference when P <0.05Result:1、The DFS have no significant difference in the patients with FOLFOX of two weeks and FOLFOXof three weeks, respectively for10.4months VS11.9months, thereare no significant difference (P=0.441).2、 Subgroup analysis: gender (male, female), pathological type (highdifferentiation, moderate differentiation, low differentiation adenocarcinoma), T stage(T2, T3, T4), N stage (N1, N2), Cancer embolus (positive, negative), preoperative CEAlevel (≥5ng/ml,<5ng/ml). The DFS have no significant difference in patients with thesubgroup analysis of FOLFOX oftwo weeks and FOLFOX of three weeks.(P>0.05).3、the incidence rate of I-II°oral mucositis in three weeks of FOLFOX regimens issignificantly higher than the incidence rate of two weeks of FOLFOX regimens (62.5%VS36.8%, P=0.023),It has statistical significance. the incidence rate of III-IV°oralmucositis in two groups has no significant difference (5.2%VS2.5%, P=0.526), otheradverse reactions in two groups included neutropenia, nausea and vomiting, diarrhea,peripheral neurotoxicity had no significant difference (P>0.05).4、Results of statistical analysis of single factor show the influencing single factorof DFS in patients with stage III colon cancer after operation are gender, Cancerembolus, preoperative CEA level, T stage, N stage, pathological type. Put theinfluencing single factor into the COX multivariate analysis, results showed: Cancerembolus, T staging, N staging state, pathological types are the independent predictors ofDFS in patients with stage III colon cancer after operation.Conclusion:1、Short-term efficacy of two weeks of FOLFOX scheme and three weeks ofFOLFOX scheme in patients with stage III colon cancer has no difference.2、Subgroup analyses: there is no difference of short-term efficacy in the twoweeks of FOLFOX scheme and three weeks of FOLFOX schemein the below subgroup:gender, pathological type, T stage, N stage, Cancer embolus, preoperative CEA level..3、the incidence rate of I-II°oral mucositis in three weeks of FOLFOX regimens ishigher than the incidence rate of two weeks of FOLFOX regimens,It has statisticalsignificance. but the patient can tolerate.4、The state of Cancer embolus of Colon cancer, T stage state, N stage state,pathological types are independent prognostic factors of DFS of stage III colon cancerafter adjuvant chemotherapy.

Related Dissertations

  1. Study of Sepia Ink-Astragalus Preparation for Relieving Damage Caused by Chemotherapy,R285.5
  2. Yu Ren- Cun Academic Thought and clinical experience in the clinical observation of combination chemotherapy in advanced gastric cancer with Yiqihuoxuejiedu side,R249
  3. Effects of Aspirin and Curcumin on COX-2, β-attention and PGE2 Expressions in Colon Cancer Cell Lines of HT-29 and SW 480 Cells,R735.35
  4. Inhibition of Conventional Chemotherapy Combined with Metronomic Chemotherapy on Breast Cancer Xenografts in Nude Mice,R737.9
  5. Comparative Analysis on CTF and CEF Regimens as Postoperative Adjuvant Chemotherapy in the Treatment of Phase Ⅱ Breast Cancer,R737.9
  6. Effects on Telomere Length of Epithelial Ovarian Cancer by Chemotherapy,R737.31
  7. The Effects of Aspirin on Tumor-related Markers of Stem Cell in the Human Colon Cancer Cell Line HT-29 and SW-480,R735.35
  8. Recurrent Ovarian Cancer Surgery Again with Surial Analysis of Relevant Factors,R737.31
  9. Clinical Observation of Pemetrexed for Treating Advanced Non-small Cell Lung Cancer,R734.2
  10. The Experimental Study of Antiangiogenic and Induction of Apoptosis by Maximum Tolerated Dose Combined with Low-dose Cyclophosphamide in Breast Cancer,R737.9
  11. Maximum Tolerated Dose Combined with Metronomic Chemoterpy on Proliferation and Angiogenesis in Treatment of Breast Cancer,R737.9
  12. Association of Expression of ERCC1/RRM1 with Survival and Resistance to Platinum Inpatients with Ⅰ-ⅢA NSCLC,R734.2
  13. Expression and Prognostic Significance of TS and BRCAl mRNA in Non-small Cell Lung Cancer,R734.2
  14. Clinical Study on Effect of Xie Shi Lung Cancer NO.2 in Malignant Pleural Effusion of Lung Cancer,R734.2
  15. A Retrospective Study on Chemotherapy-induced Amenorrhea in Premenopausal Women with Breast Cancer,R737.9
  16. Research on the Concept Learning Based on DFS,TP181
  17. Expression Changes of C-erbB-2, CXCR4 and ER-α after Neoadjuvant Chemotherapy in Breast Cancer and Their Significance,R737.9
  18. Early Evaluation Treatment Efficacy of Thermochemotherapy on Colon Cancer Cells HCT116 by 18F-FDG Uptake Rate,R735.35
  19. Proteomics Approach Screening Breast Cancer Drug Resistive and Sensitive Serum Marker,R737.9
  20. HIF-1α, SOCS-3, Bax in sudden cardiac death and myocardial tissue in formalin-fixed paraffin-embedded tissue for DNA extraction autopsy study,R541
  21. Study of the Relationship between the Expression of HIF-1α and Response to Neoadjuvant Chemotherapy in Breast Cancer,R737.9

CLC: > Medicine, health > Oncology > Gastrointestinal Cancer > Intestinal neoplasms > Colon tumor
© 2012 www.DissertationTopic.Net  Mobile